Press "Enter" to skip to content

Analysis of Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market 2019-2024: Industry Trends, Share, Size, Price, Revenue, Business Strategy, Production Technology Forecast to 2024

Europe

The “Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market” research report 2019 delivers comprehensive information about the market ranging from the establishment to the predictable growth trend. Europe Glucagon like Peptide – 1 (GLP – 1) Agonists market report provides brief analytical data of the market contenders globally using advanced methodological approaches, such as SWOT analysis, production chain, cost, sales margin, financial details, recent developments. Europe Glucagon like Peptide – 1 (GLP – 1) Agonists market report also offers market competitors that includes detailed company profiles along with company product specifications.

Market Overview:

  • The Europe glucagon-like peptide-1 (GLP-1) market is expected to witness tremendous growth during the forecast period (2019-2024), with a CAGR of 14.5%, mainly as a result of new drug launches.
  • Europe has approximately 56.3 million adults living with diabetes, and this number is expected to reach 70 million by 2023, which would represent around 10% of the total population of Europe.
  • Europe’s expenditure on diabetes is 9% of its total healthcare expenditure. Spending on diabetes largely varies among countries in Europe. It ranges from EUR 312 per capita in the Republic of Macedonia, to EUR 6,896 per capita in Norway.
  • Similarly, the prevalence is also highly varied across Europe, ranging from 2.8% in Albania to 9.8% in Portugal.
  • In high-income countries, diabetes is one of the leading causes of cardiovascular disease, blindness, kidney failure, and lower limb amputation.
  • The European region suffers from a high burden of diabetes, and its adverse health and economic consequences.
  • The disease is viewed as a serious threat, not just from a public health perspective, but also from a development perspective.
  • With risk factors, such as obesity increasing, and progressively aging populations, the diabetes epidemic is growing, especially in low- and middle-income countries of the region. It is one of the most common chronic diseases in the United Kingdom.

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/13999723

    In Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market Report, Following Companies Are Covered:

  • Novo Nordisk
  • Sanofi
  • Eli Lilly
  • AstraZeneca

    Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market 2019 report will help the industry aspirants in arranging their strategies. The measurements offered in this report will be an exact and helpful manual to shape the business development. Additionally, will Provide historical data along with a future forecast and detailed analysis and also expected opportunities.

    Scope of the Report:

  • The market is segmented by the drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), and by geography.

    Reasons for Buying Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market Report:

    • This report provides pin-point analysis for changing competitive dynamics
    • It provides a forward looking perspective on different factors driving or restraining market growth
    • It provides a five-year forecast assessed on the basis of how the market is predicted to grow
    • It helps in understanding the key product segments and their future
    • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
    • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/13999723

    Key Market Trends: – Ever Increasing Burden of Diabetes in the European Region

    As there is an exponential growth of the diabetes population, year on year, especially of type-2 diabetes, new innovative drugs are emerging in the market, for the ease of access to the patients.
    With the increase in the diabetes population, the need and demand for diabetes drugs are expected to increase.
    Other factors, such as better adoption than other therapies and government initiatives, are driving the diabetes drugs market.

    Germany to Dominate the Europe GLP-1 Market

    Among the studied countries, Germany is expected to lead the market, with a considerable 27.25% of the market share, followed by France.
    Victoza holds the highest market share in the Europe region, and a similar trend is seen in Germany too. Victoza is a once-daily injection, used to control blood glucose levels by enhancing glucose-dependent insulin secretion by beta cells, suppressing inappropriate elevated glucagon secretion.
    Trulicity is expected to have the highest growth during the forecast period (2019-2024) in the Europe region.

    The Research Document Will Answer Following Questions Such as:

    • What are the cutting-edge technologies responsible for driving the growth of the market?
    • What are the main applications of the market? What are the growth prospects to the market applications into the market?
    • At what stage of development are the key market products?
    • What are the shortcomings that has to face to become commercially viable? Is their growth and commercialization dependent on cost declines or technological/application breakthroughs?
    • What is the outlook for the industry?
    • What difference does performance characteristics of Europe Glucagon like Peptide – 1 (GLP – 1) Agonists create from those of established entities?

    Purchase this Report (Price 4000 USD for single user license) – https://www.industryresearch.co/purchase/13999723

    Detailed TOC of Europe Glucagon like Peptide – 1 (GLP – 1) Agonists Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Exenatide
    5.1.1.1 Byetta (Value and Volume 2012-2024)
    5.1.1.2 Bydureon (Value and Volume 2012-2024)
    5.1.2 Liraglutide
    5.1.2.1 Victoza (Value and Volume 2012-2024)
    5.1.3 Lixisenatide
    5.1.3.1 Lyxumia (Value and Volume 2012-2024)
    5.1.4 Dulaglutide
    5.1.4.1 Trulicity (Value and Volume 2012-2024)
    5.2 Geography
    5.2.1 Europe
    5.2.1.1 Germany (Value and Volume 2012-2024)
    5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.1.2 Spain (Value and Volume 2012-2024)
    5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.1.3 Italy (Value and Volume 2012-2024)
    5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly and AstraZeneca)
    5.2.1.4 France (Value and Volume 2012-2024)
    5.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide and Dulaglutide)
    5.2.1.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.1.5 UK (Value and Volume 2012-2024)
    5.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.1.6 Russia (Value and Volume 2012-2024)
    5.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.1.7 Rest of Europe (Value and Volume 2012-2024)
    5.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

    6 MARKET INDICATORS
    6.1 Type-1 Diabetes Population (2012-2024)
    6.2 Type-2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Novo Nordisk
    7.1.2 Sanofi
    7.1.3 Eli Lilly
    7.1.4 AstraZeneca
    7.2 MARKET SHARE ANALYSIS
    7.2.1 Novo Nordisk
    7.2.2 Sanofi
    7.2.3 Eli Lilly
    7.2.4 AstraZeneca

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Lancets Market Size 2019 Analysis By Industry Share, Emerging Demands, Growth Rate, Recent & Future Trends, Opportunity, and Forecast To 2024

    Lithium Hydroxide Market Share, Size 2019 Developing Rapidly with Recent Trends, Development, Revenue, Demand and Forecast to 2024 | Says Industryresearch.Biz

    Global Hot and Cold Water Dispensers Market Size 2019: Research Methodology, Top Manufactures and Market Size Estimate 2025

    Friction Modifiers Market 2019-2025 | Global Industry Extensive Competitive Landscape on Size, Volume, Trends, Share and Revenue with Leading Players Overview, Regional Forecast